Does Cymbalta Cause Weight Gain? What the Duloxetine Label Actually Says

Quick answer

The FDA-approved Cymbalta (duloxetine) label does not say that Cymbalta causes weight gain, and as of September 2026 it lists 5 approved indications, none of them weight management. It lists decreased appetite among the most common adverse reactions in adults, both "weight increased" and "weight decreased" in its longer list of reactions observed in adult clinical trials, and decreased weight among the most common reactions in children and adolescents. In other words, the label records weight change in both directions and does not settle the question for any one person. If you think your weight has changed on Cymbalta, the label's own instruction is clear: do not alter your dosing or stop the medicine without talking to your healthcare provider.

What is Cymbalta, and what is it approved for?

Cymbalta is the brand name for duloxetine, made by Eli Lilly and Company. Its label describes it as a serotonin and norepinephrine reuptake inhibitor, usually shortened to SNRI: it acts on two chemical messengers in the nervous system rather than on serotonin alone the way an SSRI does.

According to the current label, Cymbalta is indicated for the treatment of:

1. Major depressive disorder in adults
2. Generalized anxiety disorder in adults and in pediatric patients 7 years of age and older
3. Diabetic peripheral neuropathic pain in adults
4. Fibromyalgia in adults and in pediatric patients 13 years of age and older
5. Chronic musculoskeletal pain in adults

Three of those five are pain conditions, not mood conditions, which is why many people who take Cymbalta were never treated for depression at all. Weight management does not appear anywhere on the indication list. Cymbalta is not FDA-approved to help anyone lose weight, and nothing in this article should be read as a suggestion that it can.

Cymbalta weight gain: what the label actually prints

A drug label is the document the FDA approved for the medicine, so it is worth reading what it actually prints. Searching the Cymbalta label for the word "weight" turns up statements in three places.

Most common adverse reactions. For adults, the label's list of the most common adverse reactions across its approved uses is nausea, dry mouth, somnolence, constipation, decreased appetite, and hyperhidrosis (sweating). Weight gain is not on that list. Decreased appetite is. For pediatric patients, the most common reactions listed are decreased weight, decreased appetite, nausea, vomiting, fatigue, and diarrhea.

Other reactions observed in adult clinical trials. In the longer list of adverse reactions reported during adult trials, grouped by body system, the label prints under "Investigations" both "weight increased" and "weight decreased," side by side, without singling out either as the expected outcome.

Pediatric growth. In the section on children and adolescents, the label states: "Decreased appetite and weight loss have been observed in association with the use of SSRIs and SNRIs." It also instructs prescribers to "Perform regular monitoring of weight and growth in pediatric patients treated with CYMBALTA."

What the label does not establish

It is just as important to be honest about what the label does not say.

• It does not state that Cymbalta causes weight gain in adults.
• It does not state that Cymbalta prevents weight gain or causes weight loss in adults.
• It does not tell you how much your weight might change, in which direction, or over what period. Reactions reported in a trial population are not a prediction for any one person.
• The postmarketing section, which collects reports after a drug reaches the market, adds no weight-related entry.

So if you want a yes or no, the truthful answer from the label is: it records weight change in both directions and makes no claim about which direction applies to you.

The boxed warning, in plain words

Cymbalta carries a boxed warning, the form the FDA reserves for "certain contraindications or serious warnings, particularly those that may lead to death or serious injury" (21 CFR 201.57(c)(1)). This one is titled "Suicidal Thoughts and Behaviors." In plain language: in short-term studies, antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults. The label instructs that "In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors," and that families and caregivers should watch closely and stay in touch with the prescriber.

Why does this belong in an article about weight? Because a person unhappy with a weight change may be tempted to make a change on their own, and that is exactly the moment the label asks for closer observation and communication with the prescriber, not less.

Why stopping on your own is the wrong move

A reader worried about weight may think the simplest fix is to stop taking the medicine. The label addresses this directly.

The label lists the reactions that have occurred after stopping Cymbalta, whether the stop was abrupt or tapered: dizziness, headache, nausea, diarrhea, paresthesia (tingling or pins-and-needles sensations), irritability, vomiting, insomnia, anxiety, hyperhidrosis, and fatigue. It adds that with SSRIs and SNRIs as a class, reports after stopping have included sensory disturbances such as electric shock sensations, and that although these events are generally self-limiting, some have been reported to be severe.

The label's instruction, quoted exactly: "A gradual reduction in dosage rather than abrupt cessation is recommended whenever possible." The patient counseling section adds that patients "should be advised not to alter their dosing regimen, or stop taking CYMBALTA without consulting their healthcare provider." The Medication Guide says it in the patient's own language: "Do not stop Cymbalta without first talking to your healthcare provider."

That is the whole discipline of this page. It never recommends starting, stopping, or switching an antidepressant, because those decisions belong to you and the physician who knows your history.

Why are antidepressants and body weight linked at all?

The link is real at the population level, and less tidy than it sounds. A large population-based cohort study published in the BMJ followed adults in UK primary care for ten years and compared weight changes in people who were and were not prescribed antidepressants. Its authors wrote that "Antidepressant treatment may also be associated with weight gain, through mechanisms that are only partially understood," and concluded that the potential for weight gain should be considered when antidepressant treatment is indicated.

The same authors added that "Associations may not be causal, and residual confounding might contribute to overestimation of associations." That caveat matters for anyone trying to work out what is happening to their own body. Depression and anxiety can change appetite, sleep, and activity. Chronic pain can limit movement. Recovery from any of those conditions can change weight in either direction. The medicine, the condition it treats, and the life around both are all moving at once.

Does duloxetine cause weight gain? What the research says

There is a peer-reviewed analysis of duloxetine and body weight, drawn from the manufacturer's registration studies in major depressive disorder and published in the Primary Care Companion to The Journal of Clinical Psychiatry. Its conclusion, quoted without its figures: "Duloxetine-treated patients experienced weight loss after short-term treatment, followed by modest weight gain on longer-term treatment." The authors described the overall effect as minimal for the majority of patients.

Two honest limits apply. The analysis was conducted by the manufacturer's own researchers, which is worth knowing. And it studied people treated for depression, not the pain conditions that account for three of the five approved uses. Read it as a group average over time, not as a forecast for an individual.

What can you do if you think Cymbalta is affecting your weight?

None of the following changes your treatment. All of it makes the conversation with your prescriber more useful.

1. Keep a simple record. Note your weight at the same time of day, once a week, along with when the medicine was started and any other change in the same window: a new medicine, a change in pain, mood, or sleep, an injury, a holiday. Patterns are easier to see on paper than in memory. Reading your own medication paperwork helps; see how to read a prescription label.
2. Bring the record to the prescriber, who can weigh a weight change against the reason the medicine was started.
3. Ask what else could explain it. Thyroid function, other medicines, fluid changes, and the treated condition itself are reasonable questions to raise.
4. Do not change the dose on your own. The label's instruction not to alter the dosing regimen without consulting a healthcare provider applies to reductions as much as to stopping.
5. Do not add or substitute another medicine on your own, including anything sold online for weight loss. Prescribing decisions belong to a licensed physician.

Is there a generic duloxetine?

Yes. Generic duloxetine hydrochloride delayed-release capsules have been approved through abbreviated new drug applications, the FDA's approval route for generics. A live query of the Drugs@FDA database on the date of this article returned 19 application records for duloxetine: the original Cymbalta application, two other new drug applications for duloxetine products, and 16 abbreviated new drug applications for duloxetine hydrochloride, 13 of which list at least one product with an active prescription marketing status.

Which product you receive is a question for your prescriber and pharmacist. This article does not compare prices.

Where do FDA-approved weight-management medicines fit for someone taking Cymbalta?

Some readers arrive here already thinking about a medicine for weight itself. The honest framing is by label. There are prescription medicines the FDA has approved specifically for chronic weight management; for example, the Wegovy (semaglutide) label describes it as "a glucagon-like peptide-1 (GLP-1) receptor agonist" and states that Wegovy injection is "indicated in combination with a reduced calorie diet and increased physical activity" to reduce excess body weight and maintain weight reduction long term in people who meet the label's criteria. That is a separate class of medicine with its own label, warnings, and eligibility rules; an overview is in what a GLP-1 medication is. Nothing here suggests adding one of these medicines to an antidepressant or swapping one for the other. Whether any medicine for weight is appropriate alongside treatment for depression, anxiety, or pain is a decision for a licensed physician who can see the whole picture. The same label-first approach is applied to other medicines that come up in weight conversations without being approved for weight management: Wellbutrin, naltrexone, and topiramate.

Questions to bring to your physician

• Which of the five approved indications was Cymbalta prescribed for in my case, and is it still doing that job?
• I have kept a weight record since starting; does the timing suggest the medicine, the condition, or something else?
• Are there labs or other medicines on my list that could explain a weight change?
• If a change to my treatment were ever considered, how would it be done gradually, and what discontinuation symptoms should I watch for?
• What signs, including mood changes, should prompt me to call you before my next visit?

General questions about this article can be sent through the help page.

This article is for informational purposes only and does not constitute medical advice. Medication is prescribed only if a licensed physician determines it is appropriate. If you or someone you know is having thoughts of suicide, call or text 988 in the United States to reach the Suicide and Crisis Lifeline.